MicroRNA (miRNA) biogenesis is a tightly controlled multi-step process operated in the nucleus by the activity of the Large Drosha Complex (LDC). Through high resolution mass spectrometry (MS) analysis we discovered that the LDC is extensively methylated, with 82 distinct methylated sites associated to 16 out of 23 subunits of the LDC. The majority of these modifications occurs on arginine (R)-residues (61), leading to 86 methylation events, while 29 lysine (K)-methylation events occurs on 21 sites of the complex. Interestingly, both depletion and pharmacological inhibition of PRMT1 lead to a widespread alteration of the methylation state of the complex and induce global decrease of miRNA expression, as a consequence of the specific impairment of the pri-to-pre-miRNA processing step. In particular, we show that the reduced methylation of the ILF3 subunit of the complex is linked to its diminished binding to the target pri-miRNAs.
INTRODUCTION
MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression at the post-transcriptional level [1] [2] [3] [4] . They interact with target mRNAs by pairing with the corresponding miRNA-binding sites typically located in the 3' untranslated regions (3'UTRs) and promote their translational repression and/or degradation [2] . MicroRNAs are preferentially transcribed by RNA Polymerase II into long primary transcripts, called pri-miRNAs, that possess the 7-methyl-guanosine cap at the 5'-end, the poly-A tail at the 3'-end and the stem-loop structures, where the mature miRNA sequences are embedded [5] . Genes encoding miRNAs are located in different genomic regions: intergenic miRNAs are transcribed as separated transcriptional units; while intragenic miRNAs are transcribed together with their "host" gene, the majority encoded within introns and a few deriving from exons [6] . Interestingly, miRNA loci located in close proximity are often co-transcribed as unique transcripts, giving rise to polycistronic units, composed of 2 to 19 individual miRNA hairpins [5, 6] .
In the nucleus, the Microprocessor complex, which comprises the type-III RNase Drosha and DGCR8, processes pri-miRNAs into shorter stem-loop molecules of 60-70 nucleotides, called precursor miRNAs (pre-miRNAs) [4, 7] . DGCR8 binds to the pri-miRNA through its double strand RNA-binding domain and favors the correct positioning of the two RNase III domains of Drosha [8] [9] [10] which is a crucial step for the subsequent pri-miRNA cleavage and determination of the guide and passenger miRNA strands [11] [12] [13] [14] . Pre-miRNAs are then exported in the cytoplasm by the exportin-5 (XPO5)-RAN-GTP complex and processed by the Dicer/Trbp complex into small RNA duplexes, about 22nt-long [15] [16] [17] [18] . These duplexes are finally loaded into the RNA-Induced Silencing Complex (RISC), where the dsRNA is unwound, the passenger strand is removed and degraded, while the guide strand is retained and used for the recognition of the miRNA-binding site within the mRNA targets [19, 20] .
The tight control of microRNA biogenesis at multiple steps ensures the production of the correct levels of miRNA molecules that, in turn, fine-tune gene expression. Aberrant miRNA levels have been, in fact, observed in several pathologies, including cancer [21, 22] . The main regulation of miRNA biogenesis is achieved through the modulation of the Microprocessor activity, which is rate-limiting for the whole process. The expression and activity of the Microprocessor is controlled in multiple ways: first, Drosha and DGCR8 protein levels are tightly regulated by a double-negative feedback loop, whereby DGCR8 stabilizes Drosha protein level, which, in turn, promotes the degradation of DGCR8 transcript by cleaving two hairpins located in its 5'UTR [23, 24] . Second, although the Microprocessor alone can complete the pri-miRNAs cleavage reaction, there is evidence that various accessory proteins associate to it, and regulate its catalytic activity. So far, 21 co-factors have been described to interact with the Microprocessor, forming a bigger multi-protein complex called Large Drosha Complex (LDC). Accessory proteins comprise mainly RNA binding proteins (RBPs), such as the DEAD-box helicases DDX5 and DDX17, a number of heterogeneous ribonucleoproteins (hnRNPs), the FET proteins (FUS, EWSR, TAF15) and other factors [4, 25, 26] . They modulate the catalytic activity and define the substrate specificity of the Microprocessor, in various ways [4, 25, 27, 28] : DDX5 and DDX17, for instance, are required for the recognition and processing of specific secondary structures within a subset of pri-miRNAs [27] ; TARDBP both facilitates the binding and cleavage of specific pri-miRNAs and stabilizes Drosha levels by protecting it from the proteasome-dependent degradation [29, 30] . ILF2 (also known as NF45) and the splicing isoform known as NF90 of ILF3 were initially considered negative regulators of miRNA biogenesis, being shown to sequester some pri-miRNAs (e.g. pri-let-7a and pri-miR-21) from the Microprocessor when overexpressed [31, 32] . More recent experimental evidences based on gene knockdown experiment have, instead, demonstrated that basal ILF3 stabilizes specific pre-and mature miRNAs, thus exerting a positive regulation on the biogenesis of some miRNA [33] .
The LDC can also be regulated by post-translational modifications (PTMs): phosphorylation and acetylation stabilize the levels of DGCR8 and Drosha, respectively [34, 35] , whereas Drosha phosphorylation by the MAPK p38 promotes its cytoplasmic export and degradation [36] . In 2013, our group discovered for the first time that several LDC subunits are methylated on arginine (R) residues [37] , an observation that was further confirmed by a subsequent global methyl-proteomic study from another group [38] . However, besides the high frequency of this modification on the complex, its functional impact on the LDC-activity, and consequently miRNA biogenesis, remains elusive.
A family of 9 protein R-methyltransferases (PRMTs) can catalyze R-methylation in mammals.
They are grouped in 3 classes based on the specific reaction that they can catalyze: type-I enzymes generate both mono-methylation and asymmetric di-methylation, whereby asymmetric di-methyl arginine (ADMA) present 2 methyl-groups added to the same terminal ω-guanidino nitrogen atom; type-II enzymes catalyze symmetric di-methylation at distinct terminal ω-guanidino nitrogen atoms of R (SDMA); type-III group comprises only PRMT7 that is capable of generating exclusively mono-methyl arginine (MMA) [39, 40] . PRMT1 is the most active type-I PRMT, responsible of more than 85% of the annotated Rmethylations in the mammalian proteome [41, 42] , and it primarily modifies arginines located within the glycine-and arginine-rich sequences (RGG/RG) [43, 44] . Besides the well-known target arginine 3 on histone H4 (H4R3me2a) [45, 46] , several non-histone proteins are substrates of PRMT1, such as the transcription factor RUNX1 [47] ; the transcription elongation factor SPT5 [48] ; some enzymes involved in the DNA damage response like MRE11, 53BP1 and BRCA1 [49] [50] [51] [52] ; and several RNA binding proteins, including also the LDC subunits ILF3, EWSR1, FUS and TAF15 [41, [53] [54] [55] [56] . It has been shown in various studies that PRMT1dependent methylation can regulate proteins by affecting their subcellular localization, or interaction with both other proteins and nucleic acids, in particular RNAs [54, 55, [57] [58] [59] [60] .
Prompted by our initial evidence that LDC is hyper-methylated [37] , we set to investigate the possible role of this modification in regulating both the composition and function of the complex and consequently, miRNA biosynthesis.
Overall, this study demonstrates for the first time that extensive R-methylation of the LDC is dependent on PRMT1 and impacts on the activity of the complex, thus regulating miRNA production and overall levels.
RESULTS

In-depth characterization of the LDC methyl-proteome
To obtain an accurate representation of all possible methylations occurring on the LDC, we combined the affinity-enrichment of the complex with heavy methyl (hm)SILAC-labeling and MS-proteomics. Methionine is an essential amino acid that, in the cell, is the precursor of Sadenosyl methionine (SAM), the sole donor of methyl-groups in enzymatic methylation reactions. In a hmSILAC context, cells are grown in media containing the heavy isotopic variant of methionine, 13 CD 3 -methionine (Met4). Upon uptake, Met4 is intracellularly converted to 13 CD 3 -SAM, which serves as donor of heavy methyl-groups for lysine-(K) and Rmethyltransferases so that substrate proteins become heavy methyl-labelled. When coupled to high resolution MS, this strategy allows distinguishing with high confidence in vivo methylation events on R and K from false positive identifications, such as chemical methylation, or amino 6 acid substitutions that are isobaric to this modification [61] . In fact, in the MS spectra heavy methylated peptides result as isotopic peptide-pairs, where the heavy and the light peaks differ of unique mass-differences (deltamass, mass), on the basis of the number of methyl-groups added.
The experimental workflow designed for the characterization of the LDC methyl-proteome is summarized in Fig. 1A . Based on the preferential localization of the LDC in the nucleus, the nuclear fraction of hmSILAC-labeled cells was used as input for the immuno-precipitation (IP) of the complex (Suppl. 1A). In order to maximize the LDC protein coverage, we performed 4 independent co-immunoprecipitations (co-IPs) using as bait 4 different LDC subunits: DDX5, DGCR8, Drosha, and FUS ( Fig. 1B) . In each IP, the specific bait was efficiently precipitated and the complex was enriched over background proteins (Fig. 1C , Suppl. 1B). All subunits were reproducibly identified in the immuno-precipitated material, with an average sequence coverage of more than 30% (Suppl. 1C). Upon protein separation, digestion and MS analysis of each IP fraction, MaxQuant output data was further analysed using the hmSEEKER pipeline, in-house developed to improve the identification of genuine methyl-sites from hmSILAC MS data.
HmSEEKER searches for the isotopic peptide-pairs (doublets) among all detected MS1 peaks, allowing the identification of methyl-doublets even if only one of the two peak-counterparts is sequenced at the MS2 level (Massignani E. et al., under revision) . Through this analytical pipeline, we identified 116 methylated peptides with high confidence (Suppl. Table 1) , thus significantly extending our previous annotation [37] . The modified peptides correspond to 82 distinct R-or K-sites in total, associated to 16 out of 23 subunits of the LDC (Fig. 1E ). Notably, the majority (75%) of these modifications occurs on R-residues, of which 40% are mono-and 60% di-methylated ( Fig. 1F and 1G ). In total 61 distinct R-sites are modified, of which 27 are exclusively di-methylated, 9 only mono-methylated and 25 both mono-and di-methylated ( Fig.   1G ). Individual IPs of four selected proteins of the LDC, followed by WB profiling using antipan-methyl-R antibodies confirmed that they exist as both mono-and asymmetrical dimethylated (Suppl. 1D). Interestingly, only 21 lysines within the LDC resulted methylated, of which 72% are mono-methylated, 14% di-methylated and 14% tri-methylated. All together 13 Ksites are exclusively mono-methylated; 4 K-sites can exist as both mono-and di-methylated (14%); and 4 K-sites are mono-and tri-methylated (14%) ( Fig. 1G ). Overall, the data indicate a prevalence of arginine modification within the complex.
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Interestingly, 80% of R-methylated sites occur within Low Complexity (LC) regions ( Fig. 1H ), which have been often described to be involved in protein-protein and protein-RNA interactions [62] [63] [64] . Conversely, 86% of K-methylated sites are located outside of LC regions. This suggests that R-methylation may affect either the composition/stability of the complex or the binding of the LDC subunits with substrate miRNAs.
PRMT1 down-regulation impairs global miRNA expression
To assess whether R-methylation regulates the LDC activity, we investigated the effect that modulating this PTM could exert on miRNA biogenesis. We focused on PRMT1 because it is the most active enzyme of the PRMT family, and generated HeLa cells knocked-down (KD) for this protein by RNA interference with two distinct short hairpin RNAs (shRNAs) inserted in lentiviral constructs. Reduction of the protein level was observed upon cell transduction with the two shRNAs ( Fig. 2A ). Up to 96h post-infection, the growth of PRMT1-depleted cells was similar to control cells, transduced with the empty vector (EV) (Suppl. 2A), whereas at later time points KD cells showed a progressive growth reduction until full arrest, in accordance with the reported embryonic lethality due to PRMT1 loss, in mice [42] .
To assess the effect of PRMT1 depletion on LDC activity, we monitored the expression of two cancer-related miRNA clusters, miR-15a/16 and miR-17-92 [65, 66] , whose deregulation was mechanistically linked to the lack of some LDC subunits [67] [68] [69] . We observed a significant down-regulation of the mature miRNAs from both clusters, with this effect peaking at 72h postinfection ( Fig. 2B ). To achieve a more global view on miRNA biogenesis, we profiled miRNAs in PRMT1-depleted and control cells by both Small-RNAseq and qPCR using the Taqman human miRNA cards, 72h post-infection (Suppl. Table 2 and 3). Interestingly, we detected a pervasive miRNA down-regulation, with only a minor proportion of unchanged or up-regulated miRNAs ( Fig. 2C, 2D ). However, the effect on miRNAs was not mirrored by a change in small nucleolar RNAs (snoRNAs) ( Fig. 2E ), which indicates that PRMT1 depletion did not impact on other cellular ncRNAs. With both techniques, we confirmed the down-regulation of miR-15a/16
and miR-17-92 (Suppl. 2B).
To understand whether PRMT1 affects the biosynthesis of specific classes of miRNAs, we first focused on the analysis of intronic and intergenic miRNAs, whereby the former derive from the processing of introns and require spliceosomal components for their biogenesis, while the latter 8 are transcribed as independent transcription units [70, 71] . Observing no differential expression between the two miRNA types in PRMT1 deficient cells ( Fig. 2F ), we concluded that the reduction in miRNA processing does not depend on their genomic origin. Second, we analyzed the effect of PRMT1 on the positioning and orientation of Drosha cleavage, elaborating on the fact that miRNAs can originate from the 5" (5p) or 3" (3p) arm of the pri-miRNA hairpin depending on Drosha activity [14] . The observation that 5p and 3p miRNAs are equally regulated suggests that PRMT1 depletion does not affect directly the catalytic activity of Drosha towards one of the two arms (Supp. 2C).
PRMT1 depletion impairs the processing of primary-to-precursor miRNAs
The primary function of the LDC is to cleave nuclear pri-miRNAs into shorter pre-miRNAs.
Thus, we sought to investigate whether the global miRNA down-regulation observed upon PRMT1 depletion is caused by the specific impairment of this catalytic step. We designed quantitative real time PCR (qPCR) primers that allow distinguishing pri-from pre-miRNAs deriving from miR-15a/16 and miR-17-92 clusters and used them in combination to standard primers directed for the amplification of the mature forms ( Fig. 3A ). Quantitative PCR analysis indicated that pri-miR-15a/16 and pri-miR-17-92 levels were unchanged or even increased, upon PRMT1-depletion ( Fig. 3B ), whereas pre-and mature miRNAs were significantly reduced ( Fig.   3C and 3D). To corroborate the evidence that PRMT1 KD affects specifically pri-to-pre-miRNA processing, we also profiled the pri-and pre-miRNAs from the miR-15a/16 and 17-92 clusters upon cell separation into chromatin and nucleosolic fractions, since pri-miRNAs are more associated to chromatin while pre-miRNA are released in the nucleosol prior to cytoplasmic export. By profiling pri-miRNAs in the chromatin fraction and pre-miRNAs in the nucleosol, we confirmed that pre-miRNAs are down-regulated upon PRMT1 KD while the corresponding pri-miRNAs are unchanged ( Fig. 3E ). Overall, these findings demonstrate a mechanistic link between PRMT1 expression levels and the reaction specifically mediated by the LDC.
Modulation of PRMT1 strongly affects the methylation state of the LDC
To gain insights in the mechanism of PRMT1 regulation of the LDC activity, we characterized the expression, composition and methylation state of the complex by combining SILAC-based proteomics with the modulation of PRMT1 expression levels ( Fig. 4A ). We first chose the 9 optimal time-point to carry out these analyses, by WB-profiling mono-and asymmetric dimethylation of arginines in PRMT1 KD and OE cells compared to the respective controls (Suppl.
3A, Suppl. 3C). When PRMT1 was depleted, we observed a reduction in the level of ADMA, mirrored by an increase of MMA over time, with a peak between 72 and 96h after cell infection, in line with previous studies [72] (Suppl. 3A). On the contrary, when PRMT1 was overexpressed, we observed a positive correlation between the enzyme levels and that of ADMA and MMA starting from 48h over time, compared with EV control cells (Suppl. 3C). Both PRMT1 KD and OE cells showed the strongest changes in global protein methylation after 72h of modulation of PRMT1 expression. Interestingly, the timing of these changes corresponded to the one in which we observed the down-regulation of miRNAs ( Fig. 2 ). Hence, 72h post infection was chosen as the time point at which carrying out the MS-proteomics experiment ( Fig.   4A ). HeLa cells were metabolically labeled with either the light or the heavy isotopic variants of lysine and arginine (Arg0 and Lys0, and Arg10 and Lys8 for the light (L) and heavy (H) channels, respectively). In the "Forward" setting, EV control cells were cultured in the L medium and PRMT1 KD/OE cells in the H medium, while in the "Reverse" experiment, the L and H channels were swapped. Once harvested and mixed in 1:1 ratio, cells were fractionated into nuclear and cytoplasmic extracts (Suppl. 3B and Suppl. 3D) and a minor fraction of the nuclear extract was directly subjected to MS analysis for protein profiling of LDC (Fig. 4A ). The remaining part was used as input for the LDC immuno-enrichment, carrying out three co-IPs in parallel, using DDX5, DGCR8, and FUS as baits (Suppl. 3B). Each IP was performed in three biological replicates.
The SILAC ratios of the nuclear proteome upon PRMT1 KD did not indicate significant differences in the expression levels of the LDC subunits, compared to EV control (Fig. 4B ), a result that was further confirmed by WB analysis of various LDC proteins carried out on the whole cell lysate of PRMT1 depleted cells (Suppl. 4A). In line with these results, no major changes were detected in the mRNA expression of most LDC subunits, except for HNRNPDL, SRPK1 and TAF15 whose transcript levels appeared slightly reduced upon PRMT1 knock-down (Suppl. 4B).
The stability of the LDC protein levels correlated with the fact that the overall composition of the complex, independently evaluated upon DGCR8, DDX5 and FUS co-IPs, remained substantially unaltered upon PRMT1 depletion ( Fig. 4C and Suppl. 4C). In fact, the SILAC ratios of all subunits within each co-IP were similar to 1, indicating that the proteins were reproducibly coimmuno-precipitated within the complex using different baits. Considering that no major effects are observed at the level of LDC expression and composition after PRMT1 depletion, we hypothesized that the observed PRMT1-dependent impairment of miRNA biogenesis could be due to the alteration of the methylation state of the LDC.
We therefore analysed the methyl-proteome of the LDC upon PRMT1 KD and OE by quantitatively profiling the methyl-peptides by SILAC, in both the nuclear extract and the immuno-enriched complex. For the analysis of the LDC methylation state, we considered only methyl-peptides which were reproducibly identified in at least 2 out of 3 co-IPs ( Fig. 4D ) and identified 50 methyl-peptides displaying differences between PRMT1-modulated and control cells, of which 26 resulted statistically significant ( Fig. 4D and Suppl. Table 4 ). The number of regulated methyl-peptides is higher in the KD than in the OE cells, probably due to the fact that the basal activity of the endogenous PRMT1 is already saturating the methylation at some sites, which are therefore not free for further modification by the exogenous enzyme. Moreover, the regulated methyl-sites are high-quality identifications, since 80% was orthogonally validated by hmSILAC (Suppl. 5A, upper part). Interestingly, the number of hmSILAC-validated methylpeptides increases when only the significantly regulated peptides are considered (92%) (Suppl.
5A, lower part), which confirms on the one hand that the dynamic change of methyl-peptides is a good indicator of in vivo methylation and, on the other hand, that our high-confidence methylproteome is not yet saturated.
Unsupervised clustering analysis of the PRMT1-dependent LDC methyl-proteome showed the existence of 2 methyl-peptide clusters: cluster A collects peptides that are hyper-methylated upon PRMT1 depletion and hypo-methylated in PRMT1 overexpressing cells; cluster B includes peptides hypo-methylated in PRMT1 KD cells and whose methylation increased when PRMT1 is upregulated ( Fig. 4D and Suppl. Table 5 ). Motif enrichment analysis of all significantly regulated methyl-peptides displayed a strong enrichment of both the RGG and RG motifs, where the former is more specific for PRMT1 and the latter is a more general target sequence for the whole PRMT family [40, 73] (Fig. 4E , left panel). However, when we carried out the motif analysis separately on the peptides from the two clusters, cluster B displayed the enrichment of both motifs, whereas cluster A showed the enrichment of the sole RG motif ( Fig. 4E , right panel and Suppl. Table 5 ). The observation that cluster B displays both the expected trend of variation in dependence of PRMT1 and the RGG consensus motif, more specific for PRMT1, suggests that the corresponding methyl-sites are more likely genuine PRMT1 targets. On the contrary, the peptides in cluster A -hyper-methylated upon PRMT1 depletion and enriched for the more generic consensus sequence-may be substrates of other PRMTs when the major enzyme of the family is lacking. In cluster B, we found DDX17, DDX3X, DDX5 and HNRNPH1 proteins, hereby identified as new PRMT1 targets (Suppl. 5B). Overall by quantitative proteomics we identified and characterized the exact methyl-sites of 12 subunits of LDC, 8 of which are also significantly modulated in dependence of PRMT1 ( Fig. 4F ).
To confirm the MS-data, we used the recently described type-I PRMTs inhibitor MS023 and its homologous inactive counterpart MS094 [74] . Treatment with MS023 led to a reduction of ADMA and a parallel increase of MMA, while MS094 did not induce methyl-proteome changes (Suppl. 5C). When we carried out the protein-IP of ILF3 and TAF15 followed by WB profiling with pan-methyl antibodies we observed that their basal di-methylation level was reduced upon MS023, while remained unaltered MS094, in agreement with the proteomic data ( Fig. 4G ).
Instead, with the same approach we confirmed that DDX17 is exclusively R-mono-methylated and this modification is unaffected by MS023 (Suppl. 5D).
The results collected showing that LDC methylation is significantly affected by the modulation of PRMT1 expression or activity hints towards a key role of this modification in regulating the function of the complex and, consequently, miRNA biosynthesis.
Inhibition of PRMT1 catalytic activity impairs miRNA biogenesis by reducing the interaction of LDC components with pri-miRNAs
To confirm that PRMT1 enzymatic activity, rather than its expression, is crucial for the correct processing of miRNAs, we assessed the levels of the intermediate products of miRNA biogenesis upon HeLa cells treatment with MS023 and MS094. A time-course inhibition experiment showed that MS023 exerts its effect on global ADMA/MMA levels already 8 hours upon drug administration (Suppl. 5E). We thus profiled the expression of primary, precursor and mature miRNAs of miR-15a/16 and miR-17-92 clusters in cells treated with the drugs at different time points and observed that the levels of pre-and mature miRNAs were reduced while the pri-miRNAs were unchanged at 8 and16 hours post inhibition (Fig. 6A ). This confirms that the specific impairment of the pri-to-pre-miRNA processing step is due to the inhibition of the LDC catalytic activity.
Most of the LDC subunits identified as PRMT1 substrates by proteomics are RBPs. Moreover, their methylations occur within the RGG-rich sequences comprised in low complexity regions known to be involved in protein-RNA interactions [75] . Thus, we hypothesized that PRMT1dependent R-methylation could modulate the interaction of some of the LDC subunits with their pri-miRNA targets. We focused on ILF3 because this protein emerged as a genuine PRMT1 target by MS, with a single di-methylated site on R609 which was significantly down-regulated upon PRMT1 KD and orthogonally-validated by hmSILAC (Suppl. 6A). We set up an experiment of UV-crosslinking followed by RNA-immunoprecipitation (UV-RIP) using ILF3 as bait, in control and PRMT1 KD cells and assessed the binding of ILF3 to the pri-miRNA-15a/16
and pri-miRNA-17-92. The observation that the binding of ILF3 to both pri-miRNAs is strongly reduced upon PRMT1 depletion ( Fig. 6B ) directly links PRMT1-mediated methylation of this LDC subunit with its interaction to the pri-miRNA substrates. These data allow formulating a model whereby PRMT1 regulates miRNA biogenesis through extensive R-methylation of the Large Drosha Complex, and in which its depletion or inactivation generate aberrant miRNAs expression ( Fig. 6C ).
DISCUSSION
In this study, we took advantage of quantitative MS-based proteomics to investigate the extent, dynamicity and functional impact of R-methylation within the Large Drosha Complex. We initially combined MS-analysis with the affinity-enrichment of the complex to carry out a thorough characterization of its in vivo methylations. MS-analysis of protein methylation is particularly challenging both because this modification is isobaric to various amino acid substitutions and since chemical methylations introduced during sample preparation can be misassigned to the in vivo enzymatic modification. Thus, it has been demonstrated that label-free approaches for global analysis of methylation by MS can lead to high false discovery rate (FDR) in the absence of orthogonal validation strategies [76, 77] . Yet, the generation of robust and reliable methyl-sites dataset is crucial for biological and functional follow up studies. We took advantage of the hmSILAC labeling-currently considered the golden standard strategy to reduce the FDRs in global MS-based identification of methyl-sites [77] -to generate the largest highquality LDC methyl-proteome annotated so far.
Non-histone protein methylation, likewise other PTMs, is sub-stoichiometric and thus its analysis requires enrichment steps prior to MS. This is achieved by affinity purification strategies using pan-methyl antibodies, recently developed for global protein methylation analysis [37, 76, 78, 79] . The methyl-proteomes annotated so far using this strategy indicate MMA as the most abundant methylation type present globally. While this may truly reflect the larger extent of this methylation degree over the others, it is still difficult to rule out whether instead it is consequence of the better performance of the anti-pan-MMA antibody [79] . As a matter of fact, the quantification of the different types of methylation carried out in MEFs in the absence of affinity-enrichment steps indicated ADMA as the predominant modification [72] . In line with this evidence, we found that 60% of the methyl-arginines within the LDC are di-methylated. This suggests that pan-methyl-antibodies may introduce biases in methyl-proteomics analyses and that the protein co-IP in combination with hmSILAC-MS may lead to more realistic pictures of the extent and composition of sub-methyl-proteomes.
Upon PRMT1 modulation, we observed significant changes in the methylation state of various LDC subunits that were thus identified for the first time as PRMT1 substrates, when their methylation state positively correlated with the enzyme level and occurred within the PRMT1specific consensus motif RGG. Interestingly, our quantitative proteomic analysis also showed some peptides whose methylation was unaffected by changes of PRMT1 expression: they may be either targets of other PRMTs or constitutively methylated peptides possibly required for the correct assembly or functionality of the complex. Another subset of peptides was up-regulated in the absence of PRMT1 and enriched in the RG-motif: these may be substrates of other PRMTs, in line with the scavenging effect previously described upon PRMT1 ablation [72] .
When analyzing the LDC methyl-proteome, we noticed that none of the identified methylation events occur in the nuclear localization signals (NLSs) of EWSR1, FUS and TAF15 that were previously reported to modulate their cytoplasm-to-nucleus translocation [54, 80, 81] . In line with this, HeLa treatment with MS023 and MS094 did not affect the subcellular localization of these proteins, confirming that the methyl-sites involved in the LDC function are different from the ones defining the protein localization (Suppl. 6B).
Conversely, we discovered that 80% of R-methylations occur on LC regions enriched in RGsequences and typically involved in the interaction with RNA. According to the fact that the majority of the LDC proteins are RNA-binding proteins, we linked the wide-spread downregulation of miRNAs upon PRMT1 ablation to a possible role of R-methylation in regulating the RNA-binding properties of the LDC subunits. Our hypothesis was confirmed by the observed reduced binding of ILF3 to pri-miR-15a/16 and pri-miRNA-17-92 upon PRMT1 depletion. It is likely that this molecular effect of protein-R-methylation may be more general, affecting the RNA-binding ability of other subunits of the complex that possess RG-rich sequences, as well as other RBPs in general. Even if our findings on ILF3 suggest that R-methylation promotes protein-RNA interactions, we cannot exclude that this modification may on the contrary exert an opposit effect on other subunits of the complex, as described for instance for hnRNPA1 [82] . In fact, although methylation does not change the net charge of the arginine guanidine group, it enhances its hydrophobicity, thus enabling two possible opposite effects: on the one hand, it could interfere with the hydrogen bonds established between arginine residues and the negatively charged phosphate backbone of the RNA, thus introducing steric hindrance for protein-RNA binding [83] ; on the other hand, methylation could facilitate the stacking of methylated arginines within the bases of RNA, hereby promoting protein-RNA interactions [43] .
The emerging role of PRMT1-dependent R-methylation on miRNA biogenesis is similar to that reported for other PTMs decorating the LDC, i.e. phosphorylation and acetylation, which regulate the intracellular levels of miRNAs in response to intra-and external-stimuli [34] [35] [36] .
Interestingly, PRMTs are de-regulated in several types of cancer [39] and in particular PRMT1 overexpression was shown to positively correlate with tumor progression [84, 85] . Also, a recent study has showed that the overexpression of type-I PRMTs, including PRMT1, promotes mammary gland tumorigenesis in mice [86] . Similarly, microRNA expression is often altered in cancer, where these molecules can display either oncogenic or tumour-suppressive functions [87] [88] [89] . In addition, proteins involved in miRNA biogenesis, such as Drosha and DGCR8, have also been found mutated and de-regulated in tumours [22] , confirming the connection between aberrant LDC function, altered miRNA levels and cancer progression [20] .
In this scenario, the fact that the miRNA biogenesis depends on R-methylation and can be modulated by PRMT inhibitors hints towards the possibility of using the pharmacological inhibition of PRMTs to control miRNA levels, offering novel therapeutic perspective for cancer treatment. All media were supplemented with 10% dialyzed FBS (26400-044 Gibco, Life Technology), 1% glutamine, 100 U/mL Penicillin and 100 mg/ml Streptomycin and 10 mM HEPES pH 7.5.
MATERIALS AND METHODS
Cell culture, Heavy methyl SILAC and SILAC labeling of cells
Antibodies and chemical compounds
The following antibodies were used for immuno-precipitation and Western Blot experiments, MS023 and MS094 compounds were kindly provided by the SGC Toronto -Structural Genomic Consortium (http://www.thesgc.org/scientists/groups/toronto). Compounds were dissolved in DMSO and used at a final concentration of 10μM for the indicated timings.
Cell transduction with lentiviral vectors
PRMT1 knock-down (KD) cells were generated with a second-generation pLKO lentiviral vectors, in which specific sh-RNA targeting PRMT1 were cloned. The pLKO-Empty vector was used as control.
To overexpress PRMT1, the cDNA of the v2 isoform was amplified starting from HeLa cDNA, using the following primers:
The cDNA of PRMT1 was cloned into the pCCLsin.CPPT.PGK.GFP.WPRE lentiviral vector after plasmid linearization with PstI and SalI using the in-fusion HD EcoDry cloning plus, according to the manufacturer's instructions (Clontech Laboratories, Inc., CA). The GFP cassette was removed from the vector upon digestion with XhoI.
Cell lysis and sub-cellular fractionation
For preparation of whole cell extracts, cell pellets were lysed in 3 volumes of SDS Lysis Buffer For subsequent small RNA analysis from the same fractions, the chromatin pellet was washed with Buffer C, resuspended in Ripa Buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% SDS, 1% Triton, 1 mM EDTA, 0.1% Na Deoxycholate) and centrifuged 5 min at 13000 rpm at 4°C.
Protein co-immunoprecipitation and Western Blot analysis
Experiments of protein co-IP were performed starting from 1-2 mg of whole cell extract in Ripa Buffer supplemented with fresh PMSF and 1x Roche protease inhibitors. When using nuclear extracts as input, 1-2 mg nuclear extracts were diluted with Ripa Buffer lacking NaCl, in order to decrease NaCl concentration to 150mM. The extracts were pre-cleared 3 times with 50 μL of Dynabeads protein G (Thermo Fisher Scientific) and then the specific antibody was added and incubated overnight on a rotating wheel at 4°C. The following day, 50 μL of Dynabeads protein G pre-equilibrated in PBS supplemented with 0.5% BSA, were added to the extract and incubated for 2 h on a rotating wheel at 4°C. Beads were then washed 3 times with Ripa Buffer and then bound material was eluted by incubation with LSD Sample Buffer (NuPAGE) supplemented with 100 mM DTT, at 95°C for 5 minutes. Samples were then loaded on SDS-PAGE for subsequent WB analysis.
In-gel digestion of immunoprecipitated proteins
In gel digestion of gel-separated proteins with Trypsin, prior to MS analysis, was carried out as previously described [90] . After digestion and extraction from the gel pieces, the digested peptides were desalted and concentrated by reversed-phase chromatography onto micro-column C18 Stage Tips [91] . Peptides were then eluted from the tips with high organic solvent (80% ACN, 0.5% acetic acid), lyophilized, re-suspended in 1% TFA and subjected to LC-MS/MS analysis. 
Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS)
Assigning hmSILAC/SILAC peptide sequences using MaxQuant and data analysis
Acquired Raw data were analyzed with the integrated MaxQuant software v.1.5.5.1 and v.1.6.0.16, using the Andromeda search engine [92, 93] . The January 2016 version (UniProt Release 2016_01) of the Uniprot sequence was used for peptide identification. Enzyme specificity was set to Trypsin/P, meaning that trypsin cleavage occurs also in the presence of proline, after lysine or arginine residues. In MaxQuant, the estimated false discovery rate (FDR) of all peptide identifications was set to a maximum of 1%. The main search was performed with a mass tolerance of 6 ppm. A maximum of 3 missed cleavages were permitted, and the minimum peptide length was fixed at 7 amino acids. Carbamidomethylation of cysteine was set as a fixed modification.
hmSILAC peptide assignment and data analysis
To assign hmSILAC peptide sequences, we defined new modifications in MaxQuant (v1.5.5.1
and v.1.6.0.16) with the mass increment and residue specificities corresponding to the heavy versions of mono-methylated K/R, di-methylated K/R, and tri-methylated K. Additionally, we defined new variable modifications for heavy methionine (Met4) and oxidized heavy methionine (Met4ox). To reduce the complexity of the search, and given the computational resources available, each experimental set of raw data was analysed three times using three distinct sets of variable modifications, namely: (1) Met4, Met4ox, oxidation, mono-methyl-K/R, mono-methyl4- Then each peptide is associated to its corresponding MS1 peak in the allPeptides file. Finally, the H or L counterpart of each peak is searched among other peaks detected in the same raw data file. Because the pair is searched in msmsScans, hmSEEKER can find doublets even when one of the two counterparts has not been MS/MS sequenced, thus not appearing in the msms file. Assuming that the H and L counterpart must coelute, undergo the same ionization process and differ for a specific mass, we considered true positives the heavy/light peptide pairs that satisfied the following criteria: same charge, retention time difference between the two peptides <2 min and difference between observed and expected mass shift <7 ppm. In addition, hmSEEKER was used to automatically filter out all methylpeptides carrying a modification with a localization probability <0.75. No Andromeda Score filtering was applied. A data analysis pipeline, written in Perl, was developed in-house to process MaxQuant output. In this pipeline, the evidence.txt file was first filtered: potential contaminants and reverse sequences were removed. No Andromeda score or PTM localization probability cut-off was imposed. For quantitative analysis, methyl-peptides ratios were normalised on protein-level H/L information within each IP experiment and the median ratio of redundant methyl-peptides was calculated. To define significantly regulated methyl-peptides upon PRMT1 KD and OE, for each IP experiment, we calculated the mean and standard deviation of the unmodified peptidome distributions. We then calculated the average ratios and standard deviations among biological replicates for each IP experiment and used these parameters to define statistically significant regulated peptides.
Data analysis of identified SILAC peptides
Localization analyses of methylated peptides were performed using the Pfam database The cDNA for mRNA, pri-miRNA, pre-miRNA and miRNA profiling was produced using the reverse-transcriptase miScript II RT Kit (Qiagen) according to the manufacturer's specifications.
One tenth of the reaction was used for qPCR reactions in a 7,500HT Fast Real-Time PCR System. miScript SYBR Green PCR Kit (Qiagen) was used for miRNA and pre-miRNA analysis, following manufacturer's instruction, while mRNA and pri-miRNA were analyzed with FAST Sybr Green Master Mix (Life Technologies).
Primers used for qPCR
MicroRNAs were amplified using forward primers from miScript primer assays (Qiagen) and reverse universal primers from miScript SYBR Green PCR Kit (Qiagen). For precursor miRNAs analysis, we adapted the miScript Qiagen strategy also to precursor amplification using custom primers. For primary miRNAs, primers were designed to amplify the region upstream the first stem loop of the miRNA cluster. 
Taqman Array Human microRNAs
TaqMan Array Human microRNA A+B Cards (Applied Biosystems) were used for global miRNAs analysis, following manufacturer' specifications. Data were normalized on the geometric mean of two housekeeping genes (MammU6, U6snRNA). MicroRNAs were considered significantly up/down-regulated when miRNA expression in PRMT1 KD cells relative to the control was greater/lower than 1.5-fold changes, respectively.
Small-RNA sequencing
Total RNA extracted from PRMT1 KD (sh-1) and control cells was used as input for libraries preparation with the TruSeq Small RNA Library Prep Kit (Illumina), following manufacturer's instructions. Briefly, RNA 3' and RNA 5' adapters were sequentially ligated to the RNA. Cells were lysed with Lysis Buffer (0.5% NP-40, 0.5% NaDeoxycholate, 1x Roche protease inhibitors mixture (04693116001 MERCK), 25 U/mL Superase-RNAse inhibitor (Thermo Fisher Scientific) in PBS for 30 min at 4°C and then treated with 30 U of Turbo DNAseI (Thermo Fisher Scientific) for 30 min at 37°C. An aliquot (10%) of DNA-digested lysates was used as input while the remaining protein extract (90%) was split in two fractions and incubated overnight at 4°C with either IgG (Millipore) or anti-ILF3 (Bethyl) rabbit antibodies. The day after, protein G dynabeads (Thermo Fisher Scientific) were added and samples rocked for additional 3 hours at 4°C. Afterwards, the dynabeads were washed 4 times with Washing Buffer I (PBS supplemented with 1% NP-40, 0.5% NaDeoxycholate, 300 mM NaCl, 1x Roche protease inhibitor mix and 25 U/mL Superase-RNAse inhibitor), resuspended in RNAse-free water and treated again with Turbo DNAseI for 30 min at 37°C. The input material was treated in parallel in the same manner. The dynabeads were then washed 4 times with Washing Buffer II (PBS supplemented with 1% NP-40, 0.5% NaDeoxycholate, 300 mM NaCl, 10 mM EDTA, 1xRoche protease inhibitor and 25 U/mL Superase-RNAse inhibitor). Finally, the RNA was eluted from the beads with the Elution Buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM EDTA, 500 μg Proteinase K, 0.5% SDS), for 1 hour at 55 °C. Beads were then pelleted, the supernatants containing the first RNA eluted fraction collected in a clean Eppendorf tube and beads were resuspended in RNA-Lysis Buffer (Zymo Research), to collect additional RNA remained attached to the beads. The two RNA-collected fractions were extracted separately with the RNAextraction kit (Zymo Research) and subsequently pooled together. Finally, to remove residual genomic DNA, the RNA fractions and the input material were boiled for 2 min at 95°C, followed by 5 min incubation in ice, and then put at 37°C for 1 h in the presence of Turbo DNAseI. The RNA was finally extracted, retro-transcribed to cDNA using the miSCRIPT II RT kit (Qiagen) and analysed by qPCR, as above described. The values obtained for each immunopurifications were normalized over their respective input material and plotted in a histogram, as relative fold enrichment over the not immuno-purified RNA.
Immunofluorescence
Cells were plated on glass coverslips, fixed in 4% paraformaldehyde for 20 min at room temperature (RT) and permeabilized with PBS-0.1% Triton X-100 for 2 min on ice.
Subsequently, cells were initially incubated with PBS-2% BSA for 30 min at RT and later on with the following antibodies dissolved in PBS-2% BSA for 2 hours: anti-EWS (5g/ml); anti-TAF15 (1:500). After being washed, cells were stained with the respective Alexa Fluor 488 secondary antibody (Molecular Probes, Eugene, OR, USA) diluted 1:400 in PBS-2% BSA for 1 hour at RT. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were obtained with a Leica TCS SP2 (Leica Microsystems, Heerbrugg, Switzerland). Box-plot shows the distributions of intragenic and intergenic miRNAs upon PRMT1 KD, obtained from miRiad [96] . Only guide miRNAs were considered for the analysis. 
Figure legends
